Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) EBT (2016 - 2025)

Historic EBT for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to -$977000.0.

  • Zevra Therapeutics' EBT rose 9705.94% to -$977000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $53.6 million, marking a year-over-year increase of 15982.78%. This contributed to the annual value of -$90.1 million for FY2024, which is 9574.8% down from last year.
  • Per Zevra Therapeutics' latest filing, its EBT stood at -$977000.0 for Q3 2025, which was up 9705.94% from $76.9 million recorded in Q2 2025.
  • Over the past 5 years, Zevra Therapeutics' EBT peaked at $76.9 million during Q2 2025, and registered a low of -$33.2 million during Q3 2024.
  • Moreover, its 5-year median value for EBT was -$10.2 million (2023), whereas its average is -$4.7 million.
  • In the last 5 years, Zevra Therapeutics' EBT surged by 62211.87% in 2021 and then crashed by 65009.44% in 2024.
  • Zevra Therapeutics' EBT (Quarter) stood at -$2.7 million in 2021, then soared by 342.38% to $6.5 million in 2022, then tumbled by 407.5% to -$19.9 million in 2023, then decreased by 2.39% to -$20.4 million in 2024, then surged by 95.2% to -$977000.0 in 2025.
  • Its EBT was -$977000.0 in Q3 2025, compared to $76.9 million in Q2 2025 and -$1.9 million in Q1 2025.